By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Ventana is developing a companion diagnostic test for an oncology drug developed by Seattle Genetics and Millennium Pharmaceuticals under a deal announced today.

The companion diagnostic being developed by Ventana, a Roche company, will be for identifying patients who best respond to Adcetris (brentuximab vedotin) based on CD30 expression levels in their tissue specimens. Under the terms of the agreement, Ventana will develop, manufacture, and commercialize the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.